CTIM-25. ONCOLYTIC VIRUS FOR DIPG: THE CLINICAL EXPERIENCE WITH DNX-2401. (9th November 2020)

• Record Type: Journal Article
• Authors: M Alonso, Marta; Iñigo-Marco, Ignacio; Garcia-Moure, Marc; González-Huarriz, Marisol; Jones, Chris; MACKAY, Alan; Hulleman, Esther; Van der Lugt, Jasper; De Andrea, Carlos; Villalba, Maria; Hernandez, Ruben; Hervás, Sandra; Tamayo, Ibon; Lang, Frederick; Gomez-Manzano, Candelaria; Fueyo, Juan; Diez-Valle, Ricardo; de Larraya, Jaime Gállego-pérez; Tejada, Sonia
• Is Part Of: Neuro-oncology. Volume 22(2020)Supplement 2
• Page Start: ii38
• Page End: ii38
• Publication Date: 2020-11-09
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noaa215.159
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Despite our increased understanding of Diffuse Intrinsic Pontine Glioma (DIPG) the outcome remains dismal. Recently we showed that the virus Delta-24-RGD (DNX-2401 in the clinic) was effective in preclinical models of DIPG and had the ability to trigger an antitumor immune response. These data allowed us to propel a phase I clinical trial for newly diagnosed DIPGs (NCT03178032) where the patients received an intratumoral viral injection followed by standard radiotherapy. The main objective is to determine the safety, tolerability, and toxicity of DNX-2401. Secondary endpoints are overall survival at 12 months, percentage of responses and induced immune response against tumor. Tumor biopsy was performed through the cerebellar peduncle, followed by intratumoral injection of DNX-2401 (N=12). Three patients were treated with the D1=1x10 10 vp and because the lack of toxicity we escalated to the D2= 5x10 10 vp. The procedure was well tolerated and safe. All patients displayed a reduced tumor volume after combined treatment. We performed molecular studies in 9 out of the 12 patients. The immune cell composition of the biopsies was assessed using multiplexed quantitative immunofluorescence. T cells were hardly noticeable in these tumors while macrophages were abundant. We detected increased clonal T cell diversity following treatment with virus in peripheral blood lymphocytes when compared paired pre- and post-treatment samples from the trial. In addition, we measure pre and post treatment neutralizing antibodies and its relationship with survival. Finally, we performed functional studies using 2 cell lines isolated from patients included in this trial to assess the response to the virus (infectivity, viability, T-cell recognition). Overall, the administration of DNX2401 was safe, feasible and therapeutically beneficial in a subgroup of patients. This trial constitutes a proof of principle that aids to understand the response of DIPGs to viral therapies allowing to set the bases to improve this strategy for DIPG.